Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinician-level guide to recognizing, grading, and managing adverse events from PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) across ED, BPH, and pulmonary hypertension indications, with prescribing thresholds, drug interaction tables, and monitoring protocols.
Read clinical reviewA clinician-level monograph covering the pharmacology, approved indications, dosing, drug interactions, contraindications, and comparative data for the PDE5 inhibitor drug class, sildenafil, tadalafil, vardenafil, and avanafil.
Read clinical reviewComplete drug-drug interaction (DDI) reference for PDE5 inhibitors including sildenafil, tadalafil, vardenafil, and avanafil. CYP3A4 interactions, nitrate contraindications, alpha-blocker timing, and dose adjustments for prescribers.
Read clinical reviewA prescriber-level guide to the PDE5 inhibitor monitoring bundle, including baseline labs, on-treatment surveillance, cardiovascular screening, and follow-up intervals for sildenafil, tadalafil, vardenafil, and avanafil.
Read clinical reviewA board-reviewed, prescriber-level summary of PDE5 inhibitors across special populations including renal impairment, hepatic dysfunction, cardiovascular disease, older adults, and women, with dosing tables and guideline citations.
Read clinical reviewA prescriber-level guide to selecting among sildenafil, tadalafil, vardenafil, and avanafil, covering pharmacokinetics, indications, drug interactions, and special populations.
Read clinical review